Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses
There has been a recent resurgence of interest into new and improved vaccine adjuvants. This interest has been stimulated by the need for new vaccines to combat problematic pathogens such as SARS and HIV, and to counter potential bioterrorist attacks. A major bottleneck in vaccine development is the low immunogenicity of purified subunit or recombinant proteins, creating the need for safe human adjuvants with high potency. A major problem in the search for the ideal adjuvant is that adjuvants...[Show more]
|Collections||ANU Research Publications|
|Source:||Immunology and Cell Biology|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.